Synopsis: The Indian pharmaceutical sector faced a severe sell-off today, Thursday, April 2, 2026, with the Nifty Pharma index plunging nearly 4% (hitting an intraday low of 21,149). The crash was triggered by renewed fears of US President Donald Trump’s administration imposing a 100% tariff on branded and patented drugs, a move specifically targeting companies that do not manufacture on US soil.
Why Nifty Pharma US Tariff Fears Crashed Stocks 4%
While rising oil prices and war tensions had already dragged the broader market down, the Pharma sector took the hardest hit. Investors are panicking over a potential “National Security” investigation under Section 232 of the Trade Expansion Act, which could give the US a legal path to slap massive duties on drug imports.
The 3 Main Triggers for Today’s Decline
1. The 100% “Branded Drug” Tariff Threat
The Trump administration has suggested it will move forward with 100% tariffs on pharmaceutical companies that have not agreed to keep their US prices low or expand domestic production.
- The Impact: This directly hurts companies like Sun Pharma, which has a significant portfolio of “Specialty” and branded drugs in the US.
- The “Ground Breaking” Rule: Reports suggest exemptions will only be given to companies that have already “broken ground” or have factories under construction in America.
2. The “Section 232” Legal Loophole
Earlier attempts by the US to impose pharmaceutical tariffs were slowed down by court rulings. However, the administration is now using a “National Security“ justification.
- How it works: By labeling drug supply chains as a matter of national security, the US can bypass traditional trade rules and impose levies immediately, creating massive uncertainty for Indian exporters.
3. High Dependence on the US Market
Indian pharma companies supply nearly 40–50% of all generic medicines used in the US. While generic drugs have a partial “carve-out” for now, investors fear that the “branded” tariff is just the first step.
Any change in US pricing rules could permanently damage the profit margins of India’s biggest drugmakers.
Stock Performance: The Biggest Losers (April 2, 2026)
The decline was broad-based, with major heavyweights leading the fall.
| Company Name | Intraday Low | Today’s Fall (%) | Exposure Level |
| Sun Pharma | ₹1,657.60 | -4.1% | High (Branded & Specialty) |
| Cipla | ₹1,170.30 | -2.1% | Medium (Respiratory/Generics) |
| Laurus Labs | ₹1,343.20 | -2.2% | Medium (API/Exports) |
| Apollo Hospitals | ₹7,157.35 | -2.0% | Sentiment-based drag |
Also read about New Financial Year Blast
What This Means for a Layman
Think of the US market as a giant supermarket where India sells half of all the medicines. Today, the manager of that supermarket (the US government) said, “If you want to sell your premium medicine here, you must either build a factory in our town or pay a 100% tax.”
Because building a factory takes years and paying the tax makes the medicine too expensive to sell, investors are worried these Indian companies will lose their biggest customer.
Disclaimer: The views expressed are for informational purposes only and do not constitute financial advice. Investing in stocks and IPOs involves significant risk.forgeup.in is not liable for any financial losses. Always consult a certified investment advisor before making any decisions.